Heat Shock Proteins is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Heat shock proteins (HSPs) are a superfamily of molecular chaperones that assist in protein folding, prevent aggregation of misfolded polypeptides, and facilitate the degradation of terminally damaged proteins. Originally discovered as proteins induced by thermal stress, HSPs are now recognized as central components of the cellular proteostasis network. In neurodegenerative diseases — where toxic protein aggregates are a defining pathological feature — HSPs represent both endogenous defense mechanisms and promising therapeutic targets. Dysregulation of the heat shock response during aging and disease contributes to the accumulation of amyloid-beta], tau] protein], alpha-synuclein], and other pathogenic species that drive neuronal death.
Mammalian HSPs are classified into families based on molecular weight. Each family performs distinct but overlapping roles in proteostasis.
| Family | Gene Symbol | Molecular Weight (kDa) | Subcellular Location | Primary Function |
|---|---|---|---|---|
| Small HSPs (HSP27) | HSPB1 | 15-30 | Cytoplasm | Holdase activity; prevents aggregation of partially unfolded intermediates; anti-apoptotic |
| HSP40 | DNAJB1, DNAJA1 | 40 | Cytoplasm, ER, mitochondria | Co-chaperone for HSP70; stimulates ATPase activity; delivers substrates to HSP70 |
| HSP60 | HSPD1 | 60 | Mitochondrial matrix | Folds mitochondrial matrix proteins; assists import of nuclear-encoded mitochondrial proteins |
| HSP70 | HSPA1A (inducible), HSCA8 (constitutive) | 70 | Cytoplasm, nucleus, ER (BiP/GRP78) | ATP-dependent substrate binding and folding; disaggregation; targets clients for degradation |
| HSP90 | HSP90AA1 (inducible), HSP90AB1 (constitutive) | 90 | Cytoplasm, nucleus, ER (GRP94) | Stabilizes client protein conformations; regulates signaling kinases and transcription factors |
| HSP110 | HSPH1 | 110 | Cytoplasm | Nucleotide exchange factor for HSP70; cooperates in protein disaggregation |
HSP70 operates through an ATP-dependent cycle of substrate binding and release that is tightly regulated by co-chaperones Fernandez-Fernandez & Valpuesta, 2018. In the ATP-bound state, HSP70 adopts an open conformation with low substrate affinity and rapid exchange kinetics. The J-domain co-chaperone DNAJB1 (HSP40) delivers misfolded substrates to HSP70 and simultaneously stimulates HSP70 ATPase activity. ATP hydrolysis converts HSP70 to the ADP-bound closed conformation, which tightly grips the substrate. This clamping prevents aggregation and allows the substrate to refold. Nucleotide exchange factors, including BAG1 and HSP110/HSPH1, promote ADP release and ATP rebinding, reopening the substrate-binding domain and releasing the client — either as a refolded native protein or for another round of chaperone cycling.
When substrates fail to refold after multiple cycles, HSP70 directs them toward degradation pathways, making the chaperone a critical triage point in the proteostasis network.
The E3 ubiquitin ligase CHIP (C-terminus of Hsc70 Interacting Protein, encoded by STUB1) binds the C-terminal EEVD motif of HSP70 via its tetratricopeptide repeat (TPR) domain Soss et al., 2015. When a client protein cannot achieve its native fold, CHIP ubiquitinates the substrate while it remains bound to HSP70, tagging it for proteasomal degradation via the ubiquitin-proteasome system. CHIP can also direct substrates toward autophagy-mediated clearance. Loss-of-function mutations in CHIP cause Spinocerebellar Ataxia type 48 (SCA48), underscoring the importance of chaperone-mediated degradation for neuronal health Hayer et al., 2017. In Parkinson's Disease models, CHIP ubiquitinates alpha-synuclein oligomers in cooperation with HSP70, preventing their accumulation into fibrils and Lewy bodies Shin et al., 2005.
HSP90 stabilizes a broad repertoire of client proteins including kinases, transcription factors, and — critically for neurodegeneration — disease-associated proteins Luo et al., 2010. Key neurodegeneration-relevant clients include:
The heat shock response is orchestrated by heat shock factor 1 (HSF1), the master transcription factor that activates expression of HSP genes Gomez-Pastor et al., 2018. Under basal conditions, HSF1 is maintained in an inactive monomeric state through repressive interactions with HSP70 and HSP90. Upon proteotoxic stress, accumulating misfolded proteins titrate HSP70 and HSP90 away from HSF1, permitting HSF1 trimerization, nuclear translocation, and binding to heat shock elements (HSEs) in HSP gene promoters.
HSF1 activity declines substantially during normal aging, and this decline is exacerbated in Alzheimer's Disease Brehme et al., 2014. Postmortem studies of AD brain show reduced HSF1 protein levels, diminished DNA-binding activity, and decreased HSP70 and HSP90 expression in the hippocampus and cortex Jiang et al., 2013. Conversely, individuals who age exceptionally well appear to preserve HSF1 activation, suggesting that maintenance of the heat shock response is protective against neurodegeneration. Bidirectional interplay between HSF1 degradation and unfolded protein response activation has been shown to promote tau hyperphosphorylation] Kim et al., 2017.
In Alzheimer's Disease, the relationship between HSPs and protein aggregation is complex and sometimes paradoxical:
alpha-synuclein fibrillization — the hallmark of Parkinson's Disease and other synucleinopathies — is directly modulated by HSPs Beretta & Shala, 2022:
In amyotrophic lateral sclerosis (ALS), motor neurons are particularly vulnerable to proteotoxic stress due to high metabolic demands. Mutant SOD1, TDP-43, and FUS proteins overwhelm the chaperone network. Small HSPs, especially HSPB1 and HSPB8, are upregulated in ALS motor neurons but cannot fully compensate for the proteotoxic burden.
In Huntington's Disease, expanded polyglutamine tracts in huntingtin protein form intranuclear inclusions that sequester HSPs, depleting the available chaperone pool and creating a vicious cycle of proteostasis collapse.
Metazoans lack a dedicated protein disaggregase equivalent to yeast Hsp104, a hexameric AAA+ ATPase capable of extracting polypeptides from stable aggregates and amyloid fibrils. Shorter and colleagues engineered potentiated Hsp104 variants with enhanced disaggregase activity through directed evolution Jackrel et al., 2014. Remarkably, single missense mutations in the middle domain of Hsp104 confer the ability to suppress toxicity of TDP-43, FUS, and alpha-synuclein in yeast models. These potentiated variants dissolve pre-formed aggregates and rescue proteotoxicity, representing a novel therapeutic strategy — introduction of an exogenous disaggregase to combat neurodegenerative proteinopathies.
HSP90 inhibitors destabilize pathological client proteins by disrupting the ATP-dependent chaperone cycle Luo et al., 2010:
| Compound | Generation | Mechanism | Status |
|---|---|---|---|
| Geldanamycin | First | Binds HSP90 N-terminal ATP pocket | Preclinical (hepatotoxicity limits use) |
| 17-AAG (tanespimycin) | First | Geldanamycin derivative; reduced toxicity | Phase II (oncology); preclinical (neurodegeneration) |
| Ganetespib | Second | Synthetic triazolone; 20-fold more potent than 17-AAG | Phase III (oncology); preclinical (neurodegeneration) |
| PU-H71 | Second | Purine-scaffold inhibitor | Phase I (oncology) |
In transgenic tauopathy models, HSP90 inhibitors reduce hyperphosphorylated tau levels and improve behavioral outcomes. The challenge remains achieving CNS penetration without systemic toxicity, since HSP90 inhibitors also activate HSF1 and induce compensatory HSP70 upregulation — which may itself be neuroprotective.
Direct pharmacological activation of HSF1 represents an upstream strategy to globally boost the chaperone network. Compounds such as HSF1A and KRIBB11 modulators are in preclinical development. The appeal of this approach is that it simultaneously upregulates multiple HSPs, mimicking the full protective heat shock response.
HSPs function as an integrated proteostasis network with three major outcomes for client proteins:
The balance between these outcomes is context-dependent: acute stress favors refolding, while chronic proteotoxic stress — as in neurodegenerative disease — increasingly shifts toward degradation pathways.
Recent research (2024-2025) has focused on several promising avenues. Large HSPs (HSP110, HSP70) are being investigated for their roles in modulating neuroinflammation in addition to direct proteostasis functions Saxena et al., 2025. Structure-guided engineering of HSP104 disaggregase variants continues to improve substrate specificity and potency Tariq et al., 2019. Nanoparticle-immobilized HSP90 has demonstrated enhanced inhibition of amyloid formation in vitro, suggesting novel drug-delivery approaches. The interplay between the heat shock response and the unfolded protein response in ER is being dissected as a coordinated proteostasis network that fails during aging.
The study of Heat Shock Proteins has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.